Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug

As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, <i>The BMJ</i> raises fresh concerns over the integrity of the clinical trials that underpinned its approval. <b>Peter Doshi</b> reports

Authors

Institutions

Publication Details

Journal
BMJ
Published
2025-06-19
DOI
https://doi.org/10.1136/bmj.r1201
Citations
6
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
8.33
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug

Peter Doshi
6 citations
BMJ
Antiplatelet Therapy and Cardiovascular Diseases
8.33
article

Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug

Peter Doshi
article en
6 citations

Abstract

As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, <i>The BMJ</i> raises fresh concerns over the integrity of the clinical trials that underpinned its approval. <b>Peter Doshi</b> reports

BMJVol. 389
BMJ Group (United Kingdom)
Openalex Percentile: Top 2%
Antiplatelet Therapy and Cardiovascular Diseases
8.33
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca’s billion dollar drug — Peter Doshi · BMJ (2025) | TGRS Research Map | TGRS